Selank has been studied using several administration methods, but most published research has focused on intranasal administration. Researchers chose this route because peptides are easily degraded in the gastrointestinal system, making oral administration ineffective. Studies suggest that delivering Selank via the nasal cavity may allow the peptide to reach the central nervous system more effectively, while bypassing degradation in the digestive tract [1,2].
For this reason, intranasal administration has become the primary method used in studies analyzing the effects of Selank on anxiety, stress resistance, cognitive function, neuroprotection, gene expression, and the regulation of brain-derived neurotrophic factor (BDNF) [1–3].
Although some researchers and physicians have also analyzed subcutaneous administration, there are significantly fewer available publications compared to nasal administration. The majority of human studies described in the scientific literature concern nasal administration, not injection protocols [1,4].
How is Selank Administered?
Scientific literature describes Selank primarily as a peptide administered nasally. This route of administration was chosen due to the low oral bioavailability of peptides and their rapid degradation in the gastrointestinal tract.
Research utilizing intranasal Selank has investigated, among other things, anxiety regulation, stress adaptation, cognitive functions, neurotransmitter activity, BDNF expression, and interactions between the nervous and immune systems [1–4].
It has also been demonstrated that intranasal administration of Selank can affect gene expression in brain structures such as the hippocampus, supporting its role as a neuroactive peptide delivered via the nasal mucosa [2].
How to Use Selank?
The exact method of administration depends on the formulation used and the research objective. Published studies have utilized standardized protocols designed to evaluate specific effects, such as anxiety reduction, improved cognitive function, or neurobiological changes [1,4].
Since Selank remains a research peptide in many countries, there are currently no widely accepted guidelines for its use approved by major regulatory bodies. Most available information comes from clinical trials, experimental studies, and regional medical programs, rather than official therapeutic recommendations.
For this reason, the procedures described in scientific studies should be treated as research methods, not as general recommendations for use.
The Reconstitution of Selank
What Is Reconstitution?
Reconstitution is the process of dissolving a freeze-dried (lyophilized) peptide powder in a sterile liquid prior to use.
Many peptides, including Selank, are supplied in lyophilized form because they are more stable as a dry powder. Before use in research, the peptide is mixed with an appropriate sterile solvent to prepare a solution for a specific route of administration.
How to Reconstitute Selank?
From a laboratory perspective, reconstitution involves carefully adding a sterile solvent to a vial containing a lyophilized peptide and allowing it to fully dissolve.
However, published literature concerning Selank does not include standardized reconstitution procedures, dilution ratios, or universally accepted preparation methods. As a result, there is no single evidence-based protocol applicable to all Selank-containing products [1–4].
The preparation method may vary depending on the vial size, peptide concentration, formulation requirements, and intended route of administration. Researchers typically follow the instructions provided by the manufacturer of the product being studied.
How Do You Reconstitute 5 mg or 10 mg of Selank?
Scientific literature does not contain validated instructions for the reconstitution of vials containing 5 mg or 10 mg of Selank.
Although various dilution methods are often discussed online, they are usually based on laboratory practices rather than published clinical evidence. Since the volume of the solvent directly affects concentration, stability, and dosing accuracy, researchers generally follow the manufacturer’s instructions for a specific preparation.
In the absence of specific guidelines for a given formulation, there is no single scientifically validated answer regarding the amount of solvent needed to prepare a 5 mg or 10 mg vial.
How Much Bacteriostatic Water for 10 mg of Selank?
Current studies do not specify a standard volume of bacteriostatic water for a vial containing 10 mg of Selank.
The amount of solvent used determines the final concentration of the solution, and different experimental protocols may require different concentrations. Since there is no universally accepted concentration in the literature, the appropriate volume depends on the specific formulation.
How to Prepare a Nasal Spray with Selank?
Studies confirm that Selank can be administered intranasally; however, they do not include validated instructions for the preparation or formulation of nasal spray preparations [2,3].
Developing a stable peptide spray requires much more than simply dissolving the powder in water. Professional formulations take into account, among other things, sterility, appropriate pH, osmolality, stability, the presence of preservatives, and the rate of peptide degradation.
Because these factors directly affect the quality and shelf life of the product, the scientific literature does not provide a simple, evidence-based method for preparing a homemade Selank spray.
How Do You Mix Selank for a Nasal Spray?
Available studies show that Selank retains biological activity after intranasal administration, however, published works do not describe standardized procedures for preparing nasal spray formulations [2,3].
Consequently, there is currently no universally accepted scientific protocol specifying the exact amount of solvent, the concentration of the spray, the composition of the buffers, the preservative system, or the shelf life of a preparation containing Selank.
These parameters are usually determined during the pharmaceutical product development and formulation research process, not during clinical efficacy studies.
How Do You Reconstitute Selank for a Nasal Spray?
Most studies on intranasal Selank focus on biological effects—such as anxiety reduction, neuroprotection, BDNF regulation, antiviral activity, and effects on neurotransmitters—rather than on the chemistry of the formulation [1–4].
Therefore, despite current data indicating nasal administration as the most studied route of administration, the literature does not specify a single validated method for converting Selank powder into a ready-to-use nasal spray.
Summary
Current research indicates that intranasal administration is the most thoroughly studied method of administering Selank. Most published studies analyzing its effects on anxiety, stress resistance, cognitive function, neuroprotection, and the regulation of neurobiological processes have used this route of administration.
Despite the growing number of studies on the biological effects of Selank, there are currently no widely accepted standards regarding administration, reconstitution, or the preparation of nasal sprays. Further pharmaceutical and clinical studies will be necessary to develop standardized procedures and formulation guidelines.
Disclaimer
This material is intended solely for educational and informational purposes. Selank remains an investigational peptide in many jurisdictions, and no universally accepted standards regarding its administration, preparation, or reconstitution have been established in the published scientific literature.
For research purposes only: Selank products available at Semax Polska are intended solely for laboratory and scientific research. They are not approved for human consumption, medical use, diagnosis, treatment, or prevention of disease. All research materials should be handled by qualified personnel in accordance with applicable regulations and the principles of good laboratory practice.
References
[1] Zozulia, A. A., Neznamov, G. G., Siuniakov, T. S., Kost, N. V., Gabaeva, M. V., Sokolov, O. Y., Serebriakova, E. V., Siranchieva, O. A., Andriushenko, A. V., Telesheva, E. S., Siuniakov, S. A., Smulevich, A. B., Myasoedov, N. F., & Seredenin, S. B. (2008). Efficacy and Possible Mechanisms of Action of a New Peptide Anxiolytic Selank in the Therapy of Generalized Anxiety Disorders and Neurasthenia. Journal of Neurology and Psychiatry named after S.S. Korsakov, 108(4), 38–48. https://pubmed.ncbi.nlm.nih.gov/18454096/
[2] Levitskaya, N. G., Andreeva, L. A., Mezentseva, M. V., Shapoval, I. M., Podchernyaeva, R. Y., Shcherbenko, V. E., Potapova, L. A., Russu, L. I., Ershov, F. I., & Myasoedov, N. F. (2010). Intranasal Administration of the Peptide Selank Regulates BDNF Expression in Rat Hippocampus In Vivo. Doklady Biological Sciences, 431, 79–82.
[3] Andreeva, L. A., Nagaev, I. Y., Mezentseva, M. V., Shapoval, I. M., Podchernyaeva, R. Y., Shcherbenko, V. E., Potapova, L. A., Russu, L. I., Ershov, F. I., & Myasoedov, N. F. (2010). Antiviral Properties of Structural Fragments of the Peptide Selank. Doklady Biological Sciences, 431, 79–82. https://doi.org/10.1134/S0012496610020031
[4] Vyunova, T. V., Andreeva, L., Shevchenko, K., & Myasoedov, N. F. (2018). Peptide-Based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and Peptide Letters, 25(10), 914–923. https://doi.org/10.2174/0929866525666180925144642